Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.57 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25018783 | 1.00 | HRH4 (0.75) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL10747074 | 0.94 | HRH4 (0.84) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL9259496 | 0.94 | HRH4 (0.84) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL9637156 | 0.94 | HRH4 (0.84) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL10748421 | 0.94 | HRH4 (0.84) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL5936699 | 0.88 | HRH4 (0.96) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL9784433 | 0.86 | HRH4 (0.72) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL14288543 | 0.86 | CHRM2 (0.81) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL19217017 | 0.86 | S1PR1 (0.73) | HRH4HRH3LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL18485193 | 0.86 | CHRM2 (0.81) | HRH4HRH3LMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | HRH4 1456/4885HRH3 2194/4885LMNA 1436/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | HRH4 4097/4885HRH3 4735/4885LMNA 4550/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | HRH4 1456/4885HRH3 2194/4885LMNA 1436/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HRH4 4006/4885HRH3 4736/4885LMNA 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.